Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 2

ScienceDirect

Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study -

Patients with metastatic castration-resistant prostate cancer (mCRPC) frequently receive docetaxel after they develop resistance to abiraterone or enz…

  • 123456 Profile photo of Madelyn
    Catherine Marshall

    Be on the lookout for the phase 3 trial of pembro/docetaxel. Here are the phase 2 results of the single arm study.

Read the full article here
See more from Catherine Marshall